Vera Lady Marlina Sitorus, Zulfikar Lubis, Vinisia Setiadji, Herman Hariman


Myelodysplastic syndrome (MDS) is dysplasia or incorrect growth of blood cells in bone marrow and some have a tendency to become malignant. One of the evidence of myelodysplasia is the finding of micro-megakaryocytes in the marrow. Micro-megakaryocyte is small megakaryocyte with size of < 40 µm and has hypo-granular cytoplasm, with mono- or bi-nuclei. The introduction of micro-megakaryocyte as an evidence of MDS is still new and not too many report about this, however logically micro-megakaryocyte may produce reduce number and poor quality platelet. Therefore, this study was designed to investigate whether micro-megakaryocyte may relate to the reduction of platelet number and further to the mortality of the patients. 30 patients were recruited but later 4 were excluded due to loss of follow up. The remaining 26 cases were investigated where 17 died and 9 alive. The mean ± SEM of micro-megakaryocyte of patients who died and still alive are 61,87±3,43 and 44,63±10,28% respectively (p<0,01). Platelet levels from who died and still alive are 44,23±13,36 and 86,67±39,76 (103/µL) p<0,01. This finding shows that the increased level of micro-megakaryocyte could be use as a good prognostic marker for MDS especially in relation to mortality due to bleeding.                                                                                 


Micro-megakaryocyte, Myelodysplastic Syndrome


Liang C. Characteristic of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome. Epub. 2018

Aster JC and Stone, RM. Clinical manifestation and diagnosis of Myelodysplastic Syndrome. 2017

Foran JM and Shammo JM. Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes. The American Journal of Medicine, Vol 125. 2012; p 6-13.

Feng G, Gale RP, Wen Cui, Wenyu Cai, Gang Huang, et al. A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol. 2016.

Torlakovic EE. ICSH guidelines for the standardization of bone marrow immunohistochemistry. Pubmed. 2015.

Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. 2015.

Arber DA. The 2016 revision ti the World Health Organization Classification of Myeloid neoplasms and acute Leukemia. Blood. 2016; 127: 2391-2405

Neukirchen, Schoonen, Strupp, Gatterman, Aul, Haas, Germing. Incidence and prevalence of myelodysplastic syndromes: data from Dusseldorf MDS-registry. Leukemia Research. 2011; 35(12): 1591-1596.

Fenaux et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; Volume 25.

Oehadin dkk. Karakteristik Penderita Sindroma Mielodisplasi di Sub Bagian Hematologi-Onkologi Medik Bagian Penyakit Dalam RS Hasan Sadikin Bandung Selama 5 tahun (1997-2001).

Montoro J, Vallespi T, Sancho E, Salamero O, Lopez-Andreoni L, et al. Study of Causes of death in Patients with Myelodysplastic Syndrome: A single Institution Experience. Blood. 2011

Feng G. Impact of megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes. Blood. 2015; 126:2876

DOI: http://dx.doi.org/10.24293/ijcpml.v25i3.1389


  • There are currently no refbacks.